Lupin receives tentative approval from USFDA for Selexipag for injection
This product will be manufactured at Lupin's Nagpur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Subscribe To Our Newsletter & Stay Updated